The difference in GCD and GCR confidence scores indicates that CRSO is 100% confident that BRAF‐M + PTEN‐MD and BRAF‐M + CDKN2A‐MD are both essential combinations in a subset of melanoma patients, but is approximately 84% confident that these duos are independently sufficient to produce melanomas. Here, CDKN2A is linked to melanoma.